Search

Your search keyword '"Liu, Binliang"' showing total 47 results
Start Over Author "Liu, Binliang"
47 results on '"Liu, Binliang"'

10. Breast cancer metastases to the thyroid and stomach: A case report

Author

Bai, Xue, primary, Fang, Canbin, additional, Liu, Binliang, additional, Huagn, Jiayi, additional, Chen, Xuelian, additional, Xie, Xiaofeng, additional, Zhang, Qiuyi, additional, Liu, Meidi, additional, Liang, Jinyan, additional, Guo, Jinfeng, additional, Song, Lin, additional, Lan, Xiaofeng, additional, Chen, Liping, additional, Huang, Suni, additional, Deng, Wencui, additional, Luo, Zhenzhen, additional, and Du, Caiwen, additional

Published
2023
Full Text
View/download PDF

17. Clinical value of next-generation sequencing in guiding decisions regarding endocrine therapy for advanced HR-positive/HER-2-negative breast cancer

Author

Lyu, Dan, Liu, Binliang, Lan, Bo, Sun, Xiaoying, Li, Lixi, Zhai, Jingtong, Qian, Haili, and Ma, Fei

Subjects
Original Article
Abstract

OBJECTIVE: The mechanism of acquired gene mutation plays a major role in resistance to endocrine therapy in hormone receptor (HR)-positive advanced breast cancer. Circulating tumor DNA (ctDNA) has been allowed for the assessment of the genomic profiles of patients with advanced cancer. We performed this study to search for molecular markers of endocrine therapy efficacy and to explore the clinical value of ctDNA to guide precise endocrine therapy for HR-positive/human epidermal growth factor receptor-2 (HER-2)-negative metastatic breast cancer patients. METHODS: In this open-label, multicohort, prospective study, patients were assigned to four parallel cohorts and matched according to mutations identified in ctDNA: 1) activation of the phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway preferred mTOR inhibitor combined with endocrine therapy; 2) estrogen receptor 1 (ESR1) mutation preferred fulvestrant; 3) HER-2 mutations preferred pyrotinib; and 4) no actionable mutations received treatment according to the clinical situation. In all cohorts, patients were divided into compliance group and violation group. The primary outcome measure was progression-free survival (PFS), and the secondary outcome measure was overall survival (OS). RESULTS: In all cohorts, the combined median PFS was 4.9 months, and median PFS for the compliance and violation groups was 6.0 and 3.0 months, respectively [P=0.022, hazard ratio (HR)=0.57]. Multivariate Cox regression model showed the risk of disease progression was lower in compliance group than in violation group (P=0.023, HR=0.55). Among the patients with HER-2 mutations, the median PFS was 11.1 months in the compliance group and 2.2 months in the violation group (P=0.011, HR=0.20). There was no significant difference in the median PFS between patients who did and did not comply with the treatment protocol in patients with activation of the PI3K/AKT/mTOR or ESR1 mutation. CONCLUSIONS: The results suggest that ctDNA may help to guide the optimal endocrine therapy strategy for metastatic breast cancer patients and to achieve a better PFS. Next-generation sequencing (NGS) detection could aid in distinguishing patients with HER-2 mutation and developing new treatment strategies.

Published
2022

23. Molecular landscape ofTP53mutations in breast cancer and their utility for predicting the response to HER ‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients

Author

Liu, Binliang, primary, Yi, Zongbi, additional, Guan, Yanfang, additional, Ouyang, Quchang, additional, Li, Chunxiao, additional, Guan, Xiuwen, additional, Lv, Dan, additional, Li, Lixi, additional, Zhai, Jingtong, additional, Qian, Haili, additional, Xu, Binghe, additional, Ma, Fei, additional, and Zeng, Yixin, additional

Published
2022
Full Text
View/download PDF

25. Epithelial-Mesenchymal-Transition-Like Circulating Tumor Cell-Associated White Blood Cell Clusters as a Prognostic Biomarker in HR-Positive/HER2-Negative Metastatic Breast Cancer

Author

Guan, Xiuwen, primary, Li, Chunxiao, additional, Li, Yiqun, additional, Wang, Jiani, additional, Yi, Zongbi, additional, Liu, Binliang, additional, Chen, Hongyan, additional, Xu, Jiasen, additional, Qian, Haili, additional, Xu, Binghe, additional, and Ma, Fei, additional

Published
2021
Full Text
View/download PDF

26. Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients.

Author

Liu, Binliang, Yi, Zongbi, Guan, Yanfang, Ouyang, Quchang, Li, Chunxiao, Guan, Xiuwen, Lv, Dan, Li, Lixi, Zhai, Jingtong, Qian, Haili, Xu, Binghe, Ma, Fei, and Zeng, Yixin

Subjects
*HORMONE receptor positive breast cancer, *EPIDERMAL growth factor receptors, *CIRCULATING tumor DNA, *BREAST cancer, *METASTATIC breast cancer
Abstract

Purpose: We used targeted capture sequencing to analyze TP53‐mutated circulating tumor DNA (ctDNA) in metastatic breast cancer patients and to determine whether TP53 mutation has predictive value for anti‐human epidermal growth factor receptor 2 (HER2) treatment for in HER2 amplification‐positive patients (HER2+) and HER2 mutation‐positive, amplification‐negative (HER2−/mut) patients. Patients and Methods: TP53 mutation features were analyzed in the Geneplus cohort (n = 1184). The MSK‐BREAST cohort was used to explore the value of TP53 mutation in predicting anti‐HER‐2 antibody efficacy. Sequencing of ctDNA in phase Ib, phase Ic, phase II clinical trials of pyrotinib (HER2+ patients), and an investigator‐initiated phase II study of pyrotinib (HER2−/mut patients) were performed to analyze the relationships between TP53 mutation and prognosis for HER2 TKIs. The MSK‐BREAST cohort, MutHER, and SUMMIT cohort were used for verification. Results: TP53 mutations were detected in 53.1% (629/1184) of patients in the Geneplus cohort. The TP53 mutation rate was higher in HR‐negative (p < 0.001) and HER2 amplification‐positive (p = 0.015) patients. Among patients receiving anti‐HER2 antibody therapy, those whose tumors carried TP53 mutations had a shorter PFS (p = 0.004). However, the value of TP53 mutation in predicting HER2 TKI response was inconsistent. In HER2+ patients, no difference in PFS was observed among patients with different TP53 statuses in the combined analysis of the pyrotinib phase Ib, phase Ic, and phase II clinical trials (p = 1.00) or in the MSK‐BREAST cohort (p = 0.62). In HER2−/mut patients, TP53 mutation‐positive patients exhibited a trend toward worse prognosis with anti‐HER2 TKI treatment than TP53‐wild‐type patients in our investigator‐initiated phase II study (p = 0.15), and this trend was confirmed in the combined analysis of the MutHER and SUMMIT cohorts (p = 0.01). Conclusions: TP53 mutation can be used to identify biomarkers of anti‐HER2 antibody drug resistance in HER2+ patients and HER2 TKI resistance in HER2−/mut patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

27. Molecular Landscape of Tp53 Mutations in Breast Cancer and Their Utility for Predicting Response to HER-Targeted Therapy in HER2 Amplification-Positive and HER2 Mutation-Positive Amplification-Negative Patients

Author

Liu, Binliang, primary, Yi, Zongbi, additional, Guan, Yanfang, additional, Ouyang, Quchang, additional, Wang, Wenna, additional, Guan, Xiuwen, additional, Li, Lixi, additional, Zhai, Jintong, additional, Li, Chunxiao, additional, Qian, Haili, additional, Xu, Binghe, additional, Ma, Fei, additional, and Zeng, Yixin, additional

Published
2021
Full Text
View/download PDF

28. Development and Validation of a New Clinical Prediction Model of Catheter-Related Thrombosis Based on Vascular Ultrasound Diagnosis in Cancer Patients

Author

Liu, Binliang, primary, Xie, Junying, additional, Sun, Xiaoying, additional, Wang, Yanfeng, additional, Yuan, Zhong, additional, Liu, Xiyu, additional, Huang, Zhou, additional, Wang, Jiani, additional, Mo, Hongnan, additional, Yi, Zongbi, additional, Guan, Xiuwen, additional, Li, Lixi, additional, Wang, Wenna, additional, Li, Hong, additional, Ma, Fei, additional, and Zeng, Yixin, additional

Published
2020
Full Text
View/download PDF

32. Development and validation of a new clinical prediction model of catheter-related thrombosis in cancer patients.

Author

Liu, Binliang, primary, Xie, Junying, additional, Sun, Xiaoying, additional, Wang, Yanfeng, additional, Yuan, Zhong, additional, Liu, Xiyu, additional, Huang, Zhou, additional, Wang, Jiani, additional, Mo, Hongnan, additional, Yi, Zongbi, additional, Guan, Xiuwen, additional, Li, Lixi, additional, Wang, Wenna, additional, Li, Hong, additional, Ma, Fei, additional, and Zeng, Yi-Xin, additional

Published
2020
Full Text
View/download PDF

39. Analysis of circulating tumor DNA to monitor metastatic breast cancer patients treated with first-line chemotherapy (CAMELLIA study).

Author

Yi, Zongbi, primary, Ma, Fei, additional, Rong, Guohua, additional, Li, Jin, additional, Chang, Lianpeng, additional, Guan, Yanfang, additional, Liu, Binliang, additional, Guan, Xiuwen, additional, Li, Lixi, additional, Li, Chunxiao, additional, Zhai, Jingtong, additional, Qian, Haili, additional, and Xu, Binghe, additional

Published
2019
Full Text
View/download PDF

47. Clinical value of next-generation sequencing in guiding decisions regarding endocrine therapy for advanced HR-positive/HER-2-negative breast cancer.

Author

Lyu D, Liu B, Lan B, Sun X, Li L, Zhai J, Qian H, and Ma F

Abstract

Objective: The mechanism of acquired gene mutation plays a major role in resistance to endocrine therapy in hormone receptor (HR)-positive advanced breast cancer. Circulating tumor DNA (ctDNA) has been allowed for the assessment of the genomic profiles of patients with advanced cancer. We performed this study to search for molecular markers of endocrine therapy efficacy and to explore the clinical value of ctDNA to guide precise endocrine therapy for HR-positive/human epidermal growth factor receptor-2 (HER-2)-negative metastatic breast cancer patients., Methods: In this open-label, multicohort, prospective study, patients were assigned to four parallel cohorts and matched according to mutations identified in ctDNA: 1) activation of the phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway preferred mTOR inhibitor combined with endocrine therapy; 2) estrogen receptor 1 (ESR1) mutation preferred fulvestrant; 3) HER-2 mutations preferred pyrotinib; and 4) no actionable mutations received treatment according to the clinical situation. In all cohorts, patients were divided into compliance group and violation group. The primary outcome measure was progression-free survival (PFS), and the secondary outcome measure was overall survival (OS)., Results: In all cohorts, the combined median PFS was 4.9 months, and median PFS for the compliance and violation groups was 6.0 and 3.0 months, respectively [P=0.022, hazard ratio (HR)=0.57]. Multivariate Cox regression model showed the risk of disease progression was lower in compliance group than in violation group (P=0.023, HR=0.55). Among the patients with HER-2 mutations, the median PFS was 11.1 months in the compliance group and 2.2 months in the violation group (P=0.011, HR=0.20). There was no significant difference in the median PFS between patients who did and did not comply with the treatment protocol in patients with activation of the PI3K/AKT/mTOR or ESR1 mutation., Conclusions: The results suggest that ctDNA may help to guide the optimal endocrine therapy strategy for metastatic breast cancer patients and to achieve a better PFS. Next-generation sequencing (NGS) detection could aid in distinguishing patients with HER-2 mutation and developing new treatment strategies., (© Chinese Journal of Cancer Research. All rights reserved.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results